comparemela.com
Latest Breaking News On - Cognitive function items - Page 1 : comparemela.com
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo AXS-12 achieved statistically significant remission of cataplexy compared to placebo AXS-12 statistically.
New-york
United-states
Mark-jacobson
Darren-opland
Michael-thorpy
Axsome-therapeutics-inc
Nasdaq
Wake-disorders-center
Corporate-communications
Drug-administration
World-trade-center
Montefiore-medical-center
AXS-12 Reduces Narcolepsy Symptoms in Phase 3 Trial
Axsome Therapeutics announced topline trial results, which show AXS-12 significantly improves key narcolepsy symptoms.
Michael-thorpy
Herriot-tabuteau
Albert-einstein-college-of-medicine
Montefiore-medical-center
Wake-disorders-center
Axsome-therapeutics
Axsome-therapeutic
Clinician-global-impression
Narcolepsy-symptom-assessment
Epworth-sleepiness-scale
Cognitive-function-items
vimarsana © 2020. All Rights Reserved.